09995.HK
RemeGen Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 80.00
−1.48%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 8.0B | 3.2B | 1.7B | 1.1B | 767.8M |
| Cost of Revenue | 582.4M | 415.5M | 346.7M | 253.1M | 269.9M |
| Gross Profit | 7.4B | 2.8B | 1.4B | 823.0M | 497.8M |
| Operating Expenses | |||||
| R&D Expense | 962.7M | 1.1B | 1.6B | 1.3B | 982.1M |
| SG&A Expense | 1.6B | 1.5B | 1.3B | 1.1B | 713.2M |
| General & Admin Expense | 80.4M | 364.3M | 332.3M | 313.7M | 272.5M |
| Selling & Marketing Expense | 274.8M | 1.1B | 948.8M | 775.2M | 440.7M |
| Other Expenses | 713.4M | (440.9M) | (11.5M) | (69.8M) | (143.4M) |
| Total Operating Expenses | 2.5B | 2.1B | 2.8B | 2.3B | 1.6B |
| Cost and Expenses | 3.1B | 3.1B | 3.2B | 2.6B | 1.8B |
| Operating Income (EBIT) | 4.9B | 156.3M | (1.5B) | (1.5B) | (1.1B) |
| Non-Operating | |||||
| Interest Income | 12.8M | 4.9M | 10.2M | 28.1M | 61.5M |
| Interest Expense | 45.7M | 68.5M | 72.4M | 23.1M | 6.8M |
| Net Interest Income | (32.9M) | (63.6M) | (62.1M) | 5.1M | 54.8M |
| Other Non-Op Income/Expense | 923.0M | 554.1M | (12.7M) | (8.9M) | 55.2M |
| Non-Operating Income (excl Interest) | (7.0M) | — | (31.0M) | (13.4M) | (62.0M) |
| EBT (Pre-Tax Income) | 5.8B | 710.4M | (1.5B) | (1.5B) | (998.8M) |
| Income Tax Expense | 1.3M | 748.7K | — | — | (993.0K) |
| Bottom Line | |||||
| Net Income | 5.8B | 709.6M | (1.5B) | (1.5B) | (997.8M) |
| Earnings from Cont. Ops | 5.8B | 709.6M | (1.5B) | (1.5B) | (998.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.8B | 709.6M | (1.5B) | (1.5B) | (998.8M) |
| Per Share | |||||
| Basic EPS | HK$10.37 | HK$1.29 | (HK$2.73) | (HK$2.80) | (HK$1.88) |
| Diluted EPS | HK$10.33 | HK$1.29 | (HK$2.73) | (HK$2.80) | (HK$1.88) |
| Revenue Per Share | HK$14.19 | HK$5.90 | HK$3.19 | HK$1.99 | HK$1.45 |
| Shares | |||||
| Basic Shares Outstanding | 560.2M | 549.3M | 537.9M | 539.7M | 530.1M |
| Diluted Shares Outstanding | 562.6M | 549.3M | 537.9M | 539.7M | 531.2M |
| Profitability Metrics | |||||
| EBITDA | 5.1B | 431.7M | (1.2B) | (1.2B) | (805.7M) |
| D&A | 305.9M | 312.0M | 231.0M | 240.3M | 186.4M |
| EBIT | 4.9B | 119.7M | (1.4B) | (1.5B) | (992.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026